NCT01717664View on ClinicalTrials.gov

Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

July 31, 2016

Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
DRUG

RHB-104

95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine

Trial Locations (2)

Unknown

RedHill MS Clinical Trial Site 002, Tel Aviv

RedHill MS Clinical Trials Site 001, Zefat (Safed)

All Listed Sponsors
lead

RedHill Biopharma Limited

INDUSTRY

NCT01717664 - Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) | Biotech Hunter | Biotech Hunter